Advanced Blends
KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Repair Immunity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 80 mg
Dosing window: Anytime
Receptor / target: VEGFR2; G-Actin; MMP; Alpha-MSH
Properties: Dopamine Buffer
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 3.2mg daily | Yields exactly 2.0mg GHK-Cu, and 400mcg each of BPC-157, TB-500, and KPV. 5 days on, 2 days off (skip weekends). |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 2 mg 1x Daily | Yields 250mcg each TB-500, BPC-157, & KPV, plus 1.25mg GHK-Cu. |
| Weeks 3-4 | 4 mg 1x Daily | Yields 500mcg each TB-500, BPC-157, & KPV, plus 2.5mg GHK-Cu. |
| Weeks 5-8 | 6 mg 1x Daily | Yields 750mcg each TB-500, BPC-157, & KPV, plus 3.75mg GHK-Cu. |
| Weeks 9-12 | 4 mg 1x Daily | Yields 500mcg each TB-500, BPC-157, & KPV, plus 2.5mg GHK-Cu. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 3 mg 1x Daily | Yields 375mcg each TB-500, BPC-157, & KPV, plus 1.87mg GHK-Cu. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Blend protocols have to pass every ingredient's logic, not just the headline goal. If one ingredient conflicts with a condition, medication, or selected compound, the blend recommendation changes. Entry context: target (VEGFR2; G-Actin; MMP; Alpha-MSH); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. For blends, the highest-risk ingredient sets the caution level.
Independent evidence
Independent safety notes: No approved-label dosing was identified for this combined blend. | FDA lists BPC-157 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information for proposed routes. | FDA lists TB-500 (thymosin beta-4 fragment LKKTETQ) among withdrawn nominated bulk substances with no identified human exposure data. | FDA states it has not identified human exposure data for KPV administered by any route. | FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data.
Regulatory status: not approved multi compound blend component warnings
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Active cancer: BPC-157's VEGFR2-mediated angiogenic activity and GHK-Cu's comprehensive pro-growth gene program upregulation are absolutely contraindicated in active malignancy for the same reasons as GLOW; KPV's MC receptor-mediated anti-inflammatory activity in the tumor microenvironment is an additional consideration since tumor-associated inflammation suppression could theoretically reduce immune surveillance of the tumor. Site-only / unverified
- Zinc deficiency: GHK-Cu copper competition with zinc absorption applies identically to KLOW as to GLOW; zinc status must be confirmed and repleted before initiating KLOW; concurrent zinc supplementation (15-30mg/day) is required throughout all KLOW cycles. Site-only / unverified
- Wilson's disease: copper metabolism disorder; GHK-Cu copper delivery is absolutely contraindicated. Site-only / unverified
- Active autoimmune disease in acute flare: KPV's MC receptor-mediated anti-inflammatory activity produces immune modulation; in some autoimmune conditions, the NF-κB suppression is beneficial (IBD, psoriasis, skin inflammation); in others (systemic lupus, vasculitis, severe rheumatoid arthritis flare), the interaction between KPV's immune modulation and the existing dysregulated immune response requires medical supervision and monitoring. Site-only / unverified
- Concurrent immunosuppressive therapy (calcineurin inhibitors, biologics for autoimmune disease, post-transplant immunosuppression): KPV's MC receptor-mediated immune regulation adds an exogenous immunomodulatory layer to subjects already on potent immunosuppressive regimens; the combined immune system activity has not been characterized. Site-only / unverified
- Known hypersensitivity to BPC-157, TB-500, KPV (Lys-Pro-Val), GHK-Cu, or formulation excipients. Site-only / unverified
- Severe hepatic impairment: copper processing limitation applies identically to KLOW as GLOW. Site-only / unverified
- Pregnancy: the combined angiogenic, immune-modulatory (KPV), and copper-delivering activity of KLOW has not been evaluated during pregnancy. Site-only / unverified
- History of copper toxicity: previous copper sensitivity contraindicates the GHK-Cu component. Site-only / unverified
- Active infectious disease requiring antimicrobial management: KPV's NF-κB suppression and pro-inflammatory cytokine reduction could modestly attenuate the acute-phase inflammatory response that is part of the innate immune defense against active infection; KLOW is appropriate for post-infectious repair and maintenance and should not be used during an active systemic infection. Site-only / unverified
Side effects (site-sourced)
- Injection site redness and welting: more pronounced than GLOW in some subjects; the addition of KPV adds a fourth peptide to the injection bolus and KPV's MC1R activation in local skin can produce mild cutaneous vasodilation at the injection site; typically resolves within 1-2 hours. Site-only / unverified
- Mild fatigue: attributable to the BPC-157/TB-500 dopaminergic modulation component; similar in character and duration to GLOW; typically mild and lasting 1-3 hours post-injection. Site-only / unverified
- Zinc depletion: the same critical monitoring parameter as GLOW; mandatory zinc supplementation throughout all KLOW cycles. Site-only / unverified
- Mild copper accumulation risk: identical to GLOW; the 5-days-on protocol and cycle limits mitigate this risk at standard doses. Site-only / unverified
- Mild pigmentary changes (uncommon): KPV as an alpha-MSH receptor agonist has very modest melanocyte-stimulating activity compared to full-length alpha-MSH or Melanotan; mild, transient, and far less pronounced than Melanotan-1 or -2; not expected at the 400mcg/day KPV doses in KLOW but represents a theoretical consideration for subjects with existing pigmentation conditions. Site-only / unverified
- Transient blood pressure changes: KPV's vasodilatory activity at MC receptors in vascular endothelium may produce mild transient blood pressure fluctuations in the first days of a cycle; typically self-limiting. Site-only / unverified
- Anhedonia (rare): same BPC-157 dopaminergic mechanism as GLOW; rare; typically transient. Site-only / unverified
- Mild nausea in first cycle days: occasionally reported with the four-peptide combination; mechanism may involve KPV's area postrema MC receptor interaction; typically resolves within the first week. Site-only / unverified
- Elevated liver enzymes (ALT/AST): same hepatic copper processing consideration as GLOW; monitor in subjects with pre-existing liver conditions. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
BPC-157TB-500 (Thymosin Beta-4)KPVGHK-Cu (Copper Tripeptide-1)GLOW (BPC-157 + TB-500 + GHK-Cu)tri-heal-blend